- Home
- Products
Ukoniq (Umbralisib)
Ukoniq (Umbralisib)
- Medicine Name: Ukoniq
- Generic Name: Umbralisib
- Dosage Form & Strength: Tablets – 200 mg
- Manufactured By: TG Therapeutics, Inc
Ukoniq is a PI3K-delta and CK1-epsilon kinase inhibitor indicated for the treatment of adult patients with:
- Relapsed or refractory marginal zone lymphoma (MZL) after at least one anti-CD20-based regimen
- Relapsed or refractory follicular lymphoma (FL) after at least three prior systemic therapies
Recommended Dosage:
- 800 mg once daily, taken orally with food, until disease progression or unacceptable toxicity
- Tablets should be swallowed whole. Do not chew, crush, break, or cut
- If a dose is missed and less than 12 hours remain for the next dose, skip the missed dose
- If vomiting occurs, do not retake the dose; continue with the next scheduled dose
Serious Infections: May cause severe or fatal infections. Monitor patients regularly and withhold treatment in case of Grade 3 or 4 infections.
PJP Prophylaxis: Administer prophylaxis for Pneumocystis jirovecii pneumonia (PJP) during treatment. Permanently discontinue if PJP is confirmed.
CMV Reactivation: Monitor patients with a history of Cytomegalovirus (CMV). Consider antiviral prophylaxis.
Neutropenia: Monitor neutrophil counts biweekly during the first 2 months. Provide supportive care as needed.
Gastrointestinal Toxicity: Serious diarrhea or colitis may occur. Interrupt treatment for Grade 3 or higher GI symptoms and resume only after symptoms resolve.
Hepatotoxicity: Regularly monitor liver function. Withhold therapy if ALT/AST >5x ULN and resume at a reduced dose when levels normalize.
Cutaneous Reactions: Serious skin reactions, including exfoliative dermatitis, have been reported. Monitor and manage appropriately.
Pregnancy Warning: Ukoniq may cause fetal harm. Use effective contraception during treatment and for 30 days after the last dose. Avoid breastfeeding during and for 1 week after therapy.
To legally import Ukoniq (Umbralisib) to India via GlobalRareMeds, the following documents are required:
- Valid prescription from a qualified specialist
- Diagnostic reports supporting the indication (MZL or FL)
- Patient’s government-issued identity proof
Order Confirmation:
Orders will be processed only upon verification of required documents. An import permit may be necessary as per Indian regulations.
GlobalRareMeds sources Ukoniq 200 mg tablets from approved distributors in the USA, Canada, Europe, and Australia.
Our licensed fulfillment center in Ambernath, Thane District ensures safe handling and reliable nationwide delivery, including:
- Major Indian cities – Mumbai, Delhi, Hyderabad, Chennai, Bangalore, Kolkata, Ahmedabad, Pune, and more
- Global availability subject to compliance with local import laws
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name for Ukoniq?
A. The generic name is Umbralisib.
Q. Who manufactures Ukoniq?
A. Ukoniq is manufactured by TG Therapeutics, Inc.
Q. When was Ukoniq approved by the FDA?
A. Ukoniq was approved by the FDA on February 5, 2021.
Q. What is Ukoniq used for?
A. Ukoniq is used to treat adult patients with relapsed or refractory MZL or FL, especially when prior therapies have failed.
Q. What is the dosage and form of Ukoniq?
A. Supplied as 200 mg oral tablets, typically dosed as 800 mg once daily with food.
Q. What are the common side effects of Ukoniq?
A. Common side effects include:
Rash, fatigue, nausea, neutropenia, elevated liver enzymes, musculoskeletal pain, anemia, thrombocytopenia, upper respiratory infection, vomiting, and appetite loss.
Q. Can Ukoniq be used during pregnancy or breastfeeding?
A. No. It can cause fetal harm and is not advised during pregnancy or breastfeeding.
Q. What are the storage instructions for Ukoniq?
A. Store tablets at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (59°F to 86°F).
Q. How can I buy Ukoniq in India?
A. You can place a request through GlobalRareMeds by submitting your prescription and required documents. We ensure authentic sourcing and legal import under regulatory norms.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
